Linda Mileshkin

Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.

Paul A Cohen, Penelope M Webb, Madeleine King, Andreas Obermair, Val Gebski, Phyllis Butow, Rachael Morton, Wanda Lawson, Patsy Yates, Rachel Campbell, Tarek Meniawy, Michelle McMullen, Andrew Dean, Jeffrey Goh, Orla McNally, Linda Mileshkin, Philip Beale, Rhonda Beach, Jane Hill, Cyril Dixon, et al.

Journal article  |  2021  |  Int J Gynecol Cancer

BACKGROUND: Physical symptoms, anxiety, depression, fear of recurrence, sexual dysfunction, and social withdrawal are common in wo..

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.

Cathalijne CB Post, Ellen Stelloo, Vincent THBM Smit, Dina Ruano, Carli M Tops, Lisa Vermij, Tessa A Rutten, Ina M Jürgenliemk-Schulz, Ludy CHW Lutgens, Jan J Jobsen, Remi A Nout, Emma J Crosbie, Melanie E Powell, Linda Mileshkin, Alexandra Leary, Paul Bessette, Hein Putter, Stephanie M de Boer, Nanda Horeweg, Maartje Nielsen, et al.

Journal article  |  2021  |  J Natl Cancer Inst

BACKGROUND: Standard screening of endometrial cancer (EC) for Lynch syndrome (LS) is gaining traction; however, the prognostic imp..

Experience of a dedicated carcinoma of unknown primary clinic in an Australian comprehensive cancer centre

Arielle van Mourik, Gina Tonkin-Hill, John O'Farrell, Lavinia Tan, Tharani Sivakumaran, Hui Li Wong, Linda Mileshkin

Conference Proceedings  |  2021  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab and nivolumab in patients with rare gynaecological malignancies: Results of an Australian, multi-centre, phase 2 trial (CA209-538)

Damien Kee, Oliver Klein, Bo Gao, Ben Markman, Jessica Da Gama Duarte, Luke Quigley, Louise Jackettt, Linda Mileshkin, Richelle Linklater, Jodie Palmer, Clare Scott, Clare Matteo Carlino, Andreas Behren, Jonathan Cebon

Conference Proceedings  |  2021  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study

Ronnie Shapira Frommer, Linda Mileshkin, Ludmila Manzyuk, Nicolas Penel, Matthew Burge, Sarina Piha-Paul, Eugenia Girda, Jose Lopez Martin, Marloes van Dongen, Antoine Italiano, Lei Xu, Fan Jin, Kevin Norwood, Patrick Ott

Conference Proceedings  |  2021  |  GYNECOLOGIC ONCOLOGY

Supporting cancer care clinicians to 'hold' their patients during and beyond the COVID-19 pandemic: a role for reflective ethics discussions

Clare Delany, Joanne Benhamu, Rosalind McDougall, Danielle Ko, Hayley Jones, Linda Mileshkin, Geraldine Largey, Alex Clinch, Sarah Heynemann

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

The COVID-19 pandemic has placed an overwhelming burden on healthcare delivery globally. This paper examines how COVID-19 has affe..

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors

Antoine Italiano, Wilson H Miller, Jean-Yves Blay, Jourik A Gietema, Yung-Jue Bang, Linda R Mileshkin, Hal W Hirte, Brian Higgins, Steven Blotner, Gwen L Nichols, Lin Chi Chen, Claire Petry, Qi Joy Yang, Christophe Schmitt, Candice Jamois, Lillian L Siu

Journal article  |  2021  |  INVESTIGATIONAL NEW DRUGS

Aim The oral MDM2 antagonist idasanutlin inhibits the p53-MDM2 interaction, enabling p53 activation, tumor growth inhibition, and ..

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Yoland Antill, Peey-Sei Kok, Kristy Robledo, Sonia Yip, Michelle Cummins, Deborah Smith, Amanda Spurdle, Elizabeth Barnes, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, John Andrews, Martin R Stockler, Linda Mileshkin, et al.

Journal article  |  2021  |  J Immunother Cancer

BACKGROUND: In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of wom..

Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards

Eva Segelov, Christine Carrington, Sanchia Aranda, David Currow, John R Zalcberg, Alexander G Heriot, Linda Mileshkin, John Coutsouvelis, Jeremy L Millar, Brian T Collopy, Jon D Emery, Phoebe Zhang, Simon Cooper, Carmel O'Kane, Janet Wale, Stephen J Hancock, Anthony Sulkowski, John Bashford

Journal article  |  2021  |  MEDICAL JOURNAL OF AUSTRALIA

INTRODUCTION: The Australian Council on Healthcare Standards (ACHS) sponsored an expert-led, consensus-driven, four-stage process,..

Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Linda R Mileshkin, Kathleen N Moore, Elizabeth Barnes, Val Gebski, Kailash Narayan, Nathan Bradshaw, Yeh Chen Lee, Katrina Diamante, Anthony W Fyles, William Small, David K Gaffney, Pearly Khaw, Susan Brooks, J Spencer Thompson, Warner King Huh, Matthew Carlson, Cara Amanda Mathews, Danny Rischin, Martin R Stockler, Bradley J Monk

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

LBA3 Background: Cervical cancer is a common cause of cancer-related death among women worldwide. Standard treatment for locally ..